Artemether-lumefantrine
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Malaria
Conditions
Malaria, Falciparum
Trial Timeline
Aug 1, 2006 → Mar 1, 2007
NCT ID
NCT00386763About Artemether-lumefantrine
Artemether-lumefantrine is a phase 3 stage product being developed by Novartis for Malaria. The current trial status is completed. This product is registered under clinical trial identifier NCT00386763. Target conditions include Malaria, Falciparum.
What happened to similar drugs?
11 of 18 similar drugs in Malaria were approved
Approved (11) Terminated (1) Active (7)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00386763 | Phase 3 | Completed |
| NCT00386750 | Approved | Terminated |
| NCT00709969 | Phase 3 | Completed |
Competing Products
20 competing products in Malaria